FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Intercept Pharmaceuticals, Inc. Stock AnalysisComprehensive stock analysis for Intercept Pharmaceuticals, Inc. (ICPT) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisICPT
ICPT
Intercept Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ICPT
Home🔹Stocks🔹Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

ICPT•NASDAQ

Intercept Pharmaceuticals, Inc.

ICPT•NASDAQ
Market cap
$794.69M
Sentiment

Your view on ICPT

Mkt Cap
$794.69M
Sentiment
Your view
ICPT
Intercept Pharmaceuticals, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ICPT
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Intercept Pharmaceuticals, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Jerome B. Durso
Headquarters
US
Industry
Biotechnology
Sector
Healthcare
CEO
Jerome B. Durso
Headquarters
US
Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News